Proficio Capital Partners LLC Acquires Shares of 11,282 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Proficio Capital Partners LLC acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 11,282 shares of the specialty pharmaceutical company’s stock, valued at approximately $408,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Exchange Traded Concepts LLC raised its holdings in shares of Supernus Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock worth $800,000 after acquiring an additional 560 shares during the period. Rhumbline Advisers boosted its holdings in shares of Supernus Pharmaceuticals by 0.5% during the 4th quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company’s stock worth $6,236,000 after buying an additional 800 shares during the period. Quartz Partners LLC boosted its holdings in Supernus Pharmaceuticals by 3.0% in the 4th quarter. Quartz Partners LLC now owns 28,499 shares of the specialty pharmaceutical company’s stock valued at $1,031,000 after purchasing an additional 820 shares during the period. Assetmark Inc. boosted its holdings in Supernus Pharmaceuticals by 2.8% in the 3rd quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company’s stock valued at $1,043,000 after purchasing an additional 908 shares during the period. Finally, KBC Group NV boosted its holdings in Supernus Pharmaceuticals by 53.1% in the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock valued at $97,000 after purchasing an additional 929 shares during the period.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $32.84 on Tuesday. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The company has a 50-day simple moving average of $36.62 and a 200 day simple moving average of $35.27. The company has a market capitalization of $1.83 billion, a PE ratio of 30.69 and a beta of 0.83.

Insiders Place Their Bets

In other news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock worth $440,263 over the last quarter. 9.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on SUPN shares. StockNews.com cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.